Preclinical research finds new approach to treating aggressive cancer unresponsive to immunotherapy alone Watch Lauren Byers, M.D discuss the study’s findings. HOUSTON ― Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumor regression in mouse models of small cell lung cancer (SCLC), suggesting a promising new approach for treating patients with this aggressive cancer. The preclinical research, published today in Cancer […]
